Dr. Umit Tapan, MD
- Medicare services, 2024
- 358
- Medicare patients, 2024
- 82
- Part D claims, 2024
- 656
- Publications
- 32
- Clinical trials
- 10
- Practice address
- 1 Boston Medical Center Place, Boston, MA 02118
- Practice phone
- Call (617) 638-8000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Tapan's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Umit Tapan is a medical oncologist in Boston, Massachusetts
Dr. Tapan practices at Boston Medical Center in Boston, Massachusetts, part of Boston Medical Center Health System.
Dr. Tapan's NPI, 1457581043, was assigned on July 17, 2009. Dr. Tapan holds Massachusetts license 261972.
- NPI
- 1457581043NPI Registry (opens in a new tab)
- Medicare PAC ID
- 3476786229
- NPI enumeration date
- July 17, 2009
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Practice phone
- (617) 638-8000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 46
- Medical school graduation
- 2006
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Umit Tapan practices at Boston Medical Center in Boston, Massachusetts
Dr. Tapan's primary practice is Boston Medical Center, at 1 Boston Medical Center Place, Boston, MA 02118 in Suffolk County. The practice phone is (617) 638-8000.
- Boston Medical Center1 Boston Medical Center Place, Boston, MA 02118 · Suffolk CountyPhone(617) 638-8000
Source: Dmand AI Affiliation Data
Dr. Umit Tapan is affiliated with 2 sites of care and 1 medical group
Dr. Tapan's primary practice is Boston Medical Center in Boston, Massachusetts, part of Boston Medical Center Health System. The medical group on file is Boston University Medical Group (Boston University Internal Medicine Associates). Dmand AI also links Dr. Tapan to 1 more group practice or clinic, named with a free account. Dr. Tapan's employer is on file too: a hospital.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Umit Tapan's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tapan practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Boston Medical Center | Available with a free account |
| +1 more affiliated site | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Boston Medical Center Health System and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Umit Tapan is one of 290 medical oncologists in Massachusetts
Medical oncology is Dr. Tapan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Tapan is licensed in Massachusetts.
Specialties and state licenses
- Medical oncology, MassachusettsPrimary
Medical oncologists near Dr. Tapan
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Umit Tapan billed Medicare for 358 services in 2024
CMS data shows 358 Medicare services from Dr. Tapan across 5 procedure codes in 2024, for 82 Medicare patients. Medicare paid $27,967 for them. Every service was in a facility, such as a hospital, rather than an office.
Dr. Tapan's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 2042024: 23616%
- Other services
- 2023: 02024: 122
Dr. Tapan compared with the Massachusetts median for medical oncologists, 2024
- Dr. Tapan
- Massachusetts median
- Medicare services
- 358vs 26038% above
- Medicare patients
- 82vs 10925% below
- Part D claims
- 475vs 637.5 times
Medians across 259 medical oncologists in Massachusetts with Dmand AI profiles that report each measure.
Dr. Tapan's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Tapan?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Tapan and other medical oncologists in Massachusetts.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Umit Tapan treated 82 Medicare patients in 2024, average age 72
CMS counts 82 Medicare patients who saw Dr. Tapan in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have cancer, and 75% have high blood pressure. 72% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Tapan's median patient age at 66, with 50% women.
Dr. Tapan's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Tapan's Medicare patients by sex, 2024
- Women4049%
- Men4251%
Chronic conditions among Dr. Tapan's Medicare patients, 2024
- Cancer75%
- High blood pressure75%
- High cholesterol63%
- Diabetes41%
- Mood disorders37%
- Depression34%
- Anxiety32%
- Chronic kidney disease32%
Share of Medicare patients with each condition. A patient can have several.
Dr. Tapan's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 66
Patient panel by sex, all payers
- Women50%
- Men49%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Umit Tapan wrote 656 Medicare Part D claims in 2024
In 2024, Dr. Tapan wrote 656 Medicare Part D claims for 65 patients. 70% of them were for generic drugs. CMS names the drug for 475 of them, across 14 drugs with 11 or more claims each, at $2,015,965 in total drug cost. In 2023, CMS named 429 claims across 16 drugs.
Dr. Tapan's Part D claims by kind of drug, 2024
- Generic461 claims70%
- Brand-name195 claims30%
Dr. Tapan's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Tapan's Part D claims, 2024
- Opioids19%125 of 656 claims
- Antibiotics2%16 of 656 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 4292024: 47511%
Drugs named by CMS: 14 in 2024, 16 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Umit Tapan offers telehealth to Medicare patients
Dr. Tapan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tapan as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Source: Doctors and Clinicians National Downloadable File (CMS)
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Umit Tapan has 32 publications on record
Dmand AI links 32 papers to Dr. Tapan, published from 2011 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Safety-net Providers. Dr. Tapan has published most often in Cancer Epidemiol. Dr. Tapan's most frequent co-authors are Peter C. Everett, MD, Mohini Gautam Patel, MD and Christine Marie Bestvina, MD.
Dr. Tapan's papers by year, 2012 to 2025
Topics Dr. Tapan writes about most
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Safety-net Providers
- Black or African American
- Healthcare Disparities
- Health Status Disparities
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
Dr. Tapan's most frequent co-authors
- Peter C. Everett, MD3 shared papers
- Mohini Gautam Patel, MD3 shared papers
- Christine Marie Bestvina, MD2 shared papers
Recent publications by Dr. Tapan
Cancer Epidemiol
Community Health Equity Res Policy
See who Dr. Tapan researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Tapan works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Umit Tapan has worked on 10 clinical trials
Dmand AI links Dr. Tapan to 10 clinical trials, 6 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 7.
Clinical trials with Dr. Tapan by phase
- NonePhase 1: no trials
- 2Phase 2: 2 trials
- 1Phase 2/3: 1 trial
- 6Phase 3: 6 trials
- NonePhase 4: no trials
Conditions in Dr. Tapan's trials
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Bronchogenic
- Breast Carcinoma In Situ
- Lung Neoplasms
- Melanoma
Investigators on the most trials with Dr. Tapan
- Sheetal Sumat Acharya, MD5 shared trials
- Pablo M. Bedano, MD5 shared trials
- Brian Anthony Dicarlo, MD5 shared trials
Recent clinical trials with Dr. Tapan
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (opens in a new tab)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) (opens in a new tab)
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (opens in a new tab)
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (opens in a new tab)
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Umit Tapan received $43,535 in industry payments from 2016 to 2025
CMS Open Payments shows 57 general payments to Dr. Tapan from 8 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 51% of the total. GlaxoSmithKline, LLC. paid the most, $17,672. It also lists 1 research payment totaling $500 in 2024.
General payments to Dr. Tapan by program year, 2016 to 2025
General payments to Dr. Tapan by kind, 2016 to 2025
- Travel and lodging$22,09151%
- Consulting fees$18,27542%
- Speaker and faculty fees$2,3505%
- Food and beverage$8082%
- Education$110%
Companies that paid Dr. Tapan the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Umit Tapan's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Umit Tapan
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Umit Tapan's NPI number?
Dr. Umit Tapan's NPI number is 1457581043. It was assigned on July 17, 2009, and it is active in the NPI Registry.
What kind of doctor is Dr. Umit Tapan?
Dr. Umit Tapan is a medical oncologist in Boston, Massachusetts. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Umit Tapan practice?
Dr. Tapan practices at 1 Boston Medical Center Place, Boston, MA 02118. Dr. Tapan's primary practice is Boston Medical Center in Boston, Massachusetts, part of Boston Medical Center Health System. Dmand AI also links Dr. Tapan to 1 group practice or clinic.
What is Dr. Umit Tapan's office phone number?
The practice phone on file for Dr. Tapan is (617) 638-8000.
What is Dr. Umit Tapan's medical license number?
Dr. Tapan holds Massachusetts license 261972.
Which hospitals is Dr. Umit Tapan affiliated with?
Dr. Tapan practices at Boston Medical Center in Boston, Massachusetts.
What medical group is Dr. Umit Tapan part of?
Dr. Tapan is linked to Boston University Medical Group (Boston University Internal Medicine Associates).
Does Dr. Umit Tapan accept Medicare?
Yes. CMS data shows Dr. Tapan billed Medicare for 358 services in 2024, and Dr. Tapan accepts Medicare assignment.
Does Dr. Umit Tapan offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Tapan as offering telehealth services.
How many Medicare patients does Dr. Umit Tapan see?
CMS counts 82 Medicare patients who saw Dr. Tapan in 2024, with an average age of 72.
Show 6 more questionsShow fewer questions
What services does Dr. Umit Tapan bill to Medicare?
In 2024, Dr. Tapan's most billed Medicare services were office visit, established patient (99215), medicare service (G2211) and hospital inpatient care (99233).
What drugs does Dr. Umit Tapan prescribe most?
In 2024 Medicare Part D data, Dr. Tapan's most prescribed drugs by claims were Dexamethasone, Tagrisso and Prochlorperazine Maleate.
Has Dr. Umit Tapan received payments from drug or device companies?
CMS Open Payments shows $43,535 in general payments to Dr. Tapan from 8 companies from 2016 to 2025. The largest total came from GlaxoSmithKline, LLC.
How long has Dr. Umit Tapan been practicing?
Dr. Tapan graduated from medical school in 2006, 20 years ago.
Does Dr. Umit Tapan do research?
Dmand AI links 32 publications to Dr. Tapan, published from 2011 to 2025. Dr. Tapan has worked on 10 clinical trials.
Who does Dr. Umit Tapan publish with?
Dr. Tapan's most frequent co-authors are Peter C. Everett, MD (3 shared papers), Mohini Gautam Patel, MD (3 shared papers) and Christine Marie Bestvina, MD (2 shared papers).
Selling to medical oncology practices?
See medical oncologists in Massachusetts by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card